Fine mapping of 14q24.1 breast cancer susceptibility locus.
Phoebe Lee, Yi-Ping Fu, Jonine D Figueroa, Ludmila Prokunina-Olsson, Jesus Gonzalez-Bosquet, Peter Kraft, Zhaoming Wang, Kevin B Jacobs, Meredith Yeager, Marie-Josèphe Horner and 24 more
Article in Human genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
34 authors.
Phoebe LeeDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Yi-Ping Fu
Jonine D Figueroa
Ludmila Prokunina-Olsson
Jesus Gonzalez-Bosquet
Peter Kraft
Zhaoming Wang
Kevin B Jacobs
Meredith Yeager
Marie-Josèphe Horner
Susan E Hankinson
Amy Hutchinson
Nilanjan Chatterjee
Montserrat Garcia-Closas
Regina G Ziegler
Christine D Berg
Saundra S Buys
Catherine A McCarty
Heather Spencer Feigelson
Michael J Thun
Ryan Diver
Ross Prentice
Rebecca Jackson
Charles Kooperberg
Rowan Chlebowski
Jolanta Lissowska
Beata Peplonska
Louise A Brinton
Margaret Tucker
Joseph F Fraumeni
Robert N Hoover
Gilles Thomas
David J Hunter
Stephen J Chanock
Funding
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098233 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 2003 to 2010
$10.8M
BIOCHEMICAL MARKERS IN THE NURSES HEALTH STUDY COHORTU01CA049449 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 1995 to 2013
$5.4M
COHORT STUDY OF GENETIC SUSCEPTIBILITY TO BREAST CANCERR01CA065725 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 1996 to 2010
$4.5M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.U01CA098710 · NCI · AMERICAN CANCER SOCIETY, INC. · PI GAPSTUR, SUSAN M · 2003 to 2011
$4.2M
PREMENOPAUSAL HORMONE LEVELS AND RISK OF BREAST CANCERU01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1996 to 2001
In the National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS) genome-wide association study of breast cancer, a single nucleotide polymorphism (SNP) marker, rs999737, in the 14q24.1 interval, was associated with breast cancer risk. In order to fine map this region, we imputed a 3.93 MB region flanking rs999737 for Stages 1 and 2 of the CGEMS study (5,692 cases, 5,576 controls) using the combined reference panels of the HapMap 3 and the 1000 Genomes Project. Single-marker association testing and variable-sized sliding-window haplotype analysis were performed, and for both analyses the initial tagging SNP rs999737 retained the strongest association with breast cancer risk. Investigation of contiguous regions did not reveal evidence for an additional independent signal. Therefore, we conclude that rs999737 is an optimal tag SNP for common variants in the 14q24.1 region and thus narrow the candidate variants that should be investigated in follow-up laboratory evaluation.
Indexed as
Chromosomes, Human, Pair 14Breast NeoplasmsCase-Control StudiesChromosome MappingFemaleGenetic Predisposition to DiseaseHaplotypesHapMap ProjectHumansPolymorphism, Single Nucleotide
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fine mapping of 14q24.1 breast cancer susceptibility locus. · full record | OpenQuestion